(Q53123123)

11 May 2018

title

Recent topics on α-fetoprotein. (English)

1 reference

11 May 2018

author name string

Kazuhiko Nakao

series ordinal

1

1 reference

11 May 2018

Tatsuki Ichikawa

series ordinal

2

1 reference

11 May 2018

publication date

25 January 2013

1 reference

11 May 2018

published in

Hepatology Research

1 reference

11 May 2018

volume

43

1 reference

11 May 2018

issue

8

1 reference

11 May 2018

page(s)

820-825

1 reference

11 May 2018

Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Identification of CCAAT enhancer binding protein alpha binding sites on the human alpha-fetoprotein gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Functional mapping of tissue-specific elements of the human alpha-fetoprotein gene enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Characterization of distant enhancers and promoters in the albumin-alpha-fetoprotein locus during active and silenced expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

The alpha-fetoprotein enhancer region activates the albumin and alpha-fetoprotein promoters during liver development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Hereditary persistence of alpha-fetoprotein and H19 expression in liver of BALB/cJ mice is due to a retrovirus insertion in the Zhx2 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Determinants of serum alpha-fetoprotein levels in hepatitis C-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Effectiveness of biweekly low-dosage peginterferon treatment on the improvement of serum alanine aminotransferase and α-fetoprotein levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholest

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Impact of preoperative α-fetoprotein level on disease-free survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

A single-center retrospective analysis of liver transplantation on 255 patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

Highly sensitive Lens culinaris agglutinin-reactive α-fetoprotein: a new tool for the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FHEPR.12052

21 January 2018

Identifiers

DOI

10.1111/HEPR.12052

1 reference

11 May 2018

1 reference

11 May 2018